Pharmaceutical

Halia plans two trials testing its anti-inflammatory lead candidate

Halia Therapeutics is planning to start two Phase II trials evaluating its lead drug HT-6184 before the end of the year, said CEO David Bearss.

Aug 22, 2023 - 20:00
Halia plans two trials testing its anti-inflammatory lead candidate
Halia Therapeutics is planning to start two Phase II trials evaluating its lead drug HT-6184 before the end of the year, said CEO David Bearss.
Read the original article

Tags:

Previous Article

STAT+: As the obesity drug market grows, digital health companies juggle patient...

Next Article

Janssen’s Talvey adds European approval on top of its US authorisation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Direct-to-patient communication: Bridging the gap in medication adherence

Direct-to-patient communication: Bridging the gap in me...

Sep 28, 2024

Zucara Therapeutics receives FDA IND approval for ZT-01

Zucara Therapeutics receives FDA IND approval for ZT-01

Apr 20, 2023

Orbit and Evergreen partner to advance radiopharmaceuticals development

Orbit and Evergreen partner to advance radiopharmaceuti...

Apr 4, 2023